Biocept Operating Income from 2010 to 2026
| BIOCQ Stock | 0.0001 0.00 0.00% |
Operating Income | First Reported 2010-12-31 | Previous Quarter -28.8 M | Current Value -30.2 M | Quarterly Volatility 7.1 M |
Check Biocept financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biocept's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 300.3 K or Selling General Administrative of 12.6 M, as well as many indicators such as Price To Sales Ratio of 0.13, Dividend Yield of 0.0 or PTB Ratio of 0.32. Biocept financial statements analysis is a perfect complement when working with Biocept Valuation or Volatility modules.
Biocept | Operating Income | Build AI portfolio with Biocept Stock |
Latest Biocept's Operating Income Growth Pattern
Below is the plot of the Operating Income of Biocept over the last few years. Operating Income is the amount of profit realized from Biocept operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Biocept is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Biocept's Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biocept's overall financial position and show how it may be relating to other accounts over time.
| Operating Income | 10 Years Trend |
|
Operating Income |
| Timeline |
Biocept Operating Income Regression Statistics
| Arithmetic Mean | (23,729,707) | |
| Coefficient Of Variation | (29.79) | |
| Mean Deviation | 4,271,659 | |
| Median | (23,056,939) | |
| Standard Deviation | 7,068,489 | |
| Sample Variance | 50T | |
| Range | 29.6M | |
| R-Value | (0.27) | |
| Mean Square Error | 49.4T | |
| R-Squared | 0.07 | |
| Significance | 0.29 | |
| Slope | (377,945) | |
| Total Sum of Squares | 799.4T |
Biocept Operating Income History
About Biocept Financial Statements
Biocept shareholders use historical fundamental indicators, such as Operating Income, to determine how well the company is positioned to perform in the future. Although Biocept investors may analyze each financial statement separately, they are all interrelated. The changes in Biocept's assets and liabilities, for example, are also reflected in the revenues and expenses on on Biocept's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Operating Income | -28.8 M | -30.2 M |
Pair Trading with Biocept
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biocept position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biocept will appreciate offsetting losses from the drop in the long position's value.Moving against Biocept Stock
The ability to find closely correlated positions to Biocept could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biocept when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biocept - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biocept to buy it.
The correlation of Biocept is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biocept moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biocept moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biocept can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Biocept Stock Analysis
When running Biocept's price analysis, check to measure Biocept's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocept is operating at the current time. Most of Biocept's value examination focuses on studying past and present price action to predict the probability of Biocept's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biocept's price. Additionally, you may evaluate how the addition of Biocept to your portfolios can decrease your overall portfolio volatility.